# Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

> **NCT02714634** · PHASE4 · RECRUITING · sponsor: **University Hospital, Strasbourg, France** · enrollment: 286 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Insufficient Response to Methotrexate or Leflunomide

## Interventions

- **DRUG:** Methotrexate + targeted therapy administration
- **DRUG:** methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration

## Key facts

- **NCT ID:** NCT02714634
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-03-30
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02714634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02714634, "Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02714634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*